Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The acute effects of i.v. somatostatin (250 mcg bolus followed by 250 mcg/h continuous infusion for two hours) on renal hemodynamics, renal electrolyte and water handling, and urinary excretion of catecholamines and prostaglandins, as well as on plasma concentrations of arginine vasopressin, atrial natriuretic factor, norepinephrine, epinephrine, dopamine, glucagon, and plasma renin activity were studied in seven normal subjects. Somatostatin decreased effective renal plasma flow and glomerular filtration rate, osmotic and free water clearances, urine volume, and sodium and potassium excretion, while urinary osmolality, fractional excretion of sodium, and phosphate excretion increased significantly. Plasma concentrations of arginine vasopressin, atrial natriuretic factor, norepinephrine, epinephrine, and dopamine remained unchanged, while plasma renin activity (3.0 +/- 0.25 vs 2.4 +/- 0.2 ng AngI/ml/h; p less than 0.01) and glucagon levels (40 +/- 11 vs 20 +/- 16 pg/ml; p less than 0.01) decreased. Urinary excretion of norepinephrine, epinephrine, dopamine, PGE2, and PGF2 alpha was suppressed under somatostatin. A significant positive correlation was found between urinary dopamine and sodium excretion (r = 0.7; p less than 0.001) and urinary prostaglandin E2 and glomerular filtration (r = 0.52; p less than 0.01). Without accompanying changes in plasma osmolality and vasopressin concentration significant antidiuresis occurred, suggesting a direct tubular effect of somatostatin. However, the hormone-induced changes are due mainly to the decrease in renal plasma flow. The results demonstrate that somatostatin at supraphysiological doses exerts significant effects on the kidney.
 ...
PMID:Effect of somatostatin on kidney function and vasoactive hormone systems in health subjects. 168 Nov 32

Ten male healthy volunteers were studied in order to determine whether the synthetic somatostatin analogue Sandostatin (SMS 201-995) has effects similar to those of natural somatostatin on renal water and electrolyte excretion. The study was carried out in three separate placebo-controlled randomized double-blind cross-over trials. The subjects received single sc injections of 100 micrograms Sandostatin and placebo under conditions of mild diuresis (trial 1), water load with enhanced diuresis (trial 2), and water load with exogenous lysin-vasopressin (5 IU sc) induced antidiuresis (trial 3). The following parameters were measured: urine flow rate, serum and urine osmolalities, osmolar clearance, free water and creatinine clearances, excretion rates of sodium, potassium, calcium, chloride, and phosphate, and immunoreactive insulin. A marked antidiuretic effect was observed within 2 h after dosing in all three trials. Urine flow rates were reduced by 45% in trial 1 and by 29 and 31% in trials 2 and 3, respectively (all P less than 0.05). There were no differences in effects on serum and urine osmolalities between Sandostatin and placebo. Osmolar clearance was significantly reduced in trial 1 (P less than 0.01). Free water clearance significantly decreased only in trial 2 (P less than 0.05). Sodium excretion decreased by 49, 48 and 67%, respectively, the differences being significant in trials 1 and 3 (P less than 0.05). Calcium excretion decreased by 66, 70 and 54% (all P less than 0.001). Chloride excretion decreased by 28, 22 and 44%, the differences being significant in trials 2 and 3 (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Antidiuretic effect of Sandostatin (SMS 201-995) in healthy volunteers. 265 54

Effects of somatostatin (SRIF) on vasopressin-stimulated antidiuresis and on cyclic AMP in renal medulla in vivo and in microdissected tubule segments were examined in rats. An intravenous infusion of SRIF abolished vasopressin-induced antidiuresis without significant changes in urinary solutes and creatinine excretion in water diuresing rats: urinary osmolality rose from 131 +/- 12 to 587 +/- 20 mOsm/kg H2O in rats receiving vasopressin while urinary osmolality rose from 103 +/- 7 to only 258 +/- 25 mOsm/kg H2O in response to vasopressin with SRIF. This effect of SRIF was reversible. SRIF diminished only slightly the vasopressin-stimulated increases in cyclic AMP in renal medulla in vivo. In both cortical and medullary collecting tubules as well as in the medullary thick ascending limb of Henle's loop microdissected from rat kidney, SRIF partially inhibited vasopressin-dependent increases in cell cyclic AMP concentrations. These data demonstrate an inhibition by SRIF of vasopressin-stimulated anti-diuresis in rats and suggest that the mechanisms involved may be, at least partly, an inhibition of cyclic AMP formation in response to vasopressin in the collecting tubules.
 ...
PMID:Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. 613 12